Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. (Q40357536)
scientific article published on 17 January 2006
Language:
(P31) (Q13442814)
(P50) (Q30511642)
(P304) 563-570
(P433) 4
(P478) 17
(P577) Tuesday, January 17, 2006
(P921) (Q42824827)
(Q181600)
(Q18975855)
(Q416975)
(Q506253)
(P1433) (Q326122)
(P1476) "Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG." (language: en)
(P2093) D Schadendorf
S Ugurel
B Schuler-Thurner
F O Nestle
A Enk
E-B Bröcker
S Grabbe
W Rittgen
L Edler
A Sucker
C Zimpfer-Rechner
T Berger
J Kamarashev
G Burg
A Tüttenberg
J C Becker
P Keikavoussi
E Kämpgen
G Schuler
DC study group of the DeCOG
(P2860) (Q24548229)
(Q24799742)
other details
description scientific article published on 17 January 2006

External Links